Rodman & Renshaw announced Aytu BioScience (OTCMKTS:AYTU), boosting its stock price target to $9.00 today
- Updated: September 25, 2016
Yesterday Aytu BioScience (OTCMKTS:AYTU) traded 1.47% higher at $3.45. The company’s 50-day moving average is $3.69 and its 200-day moving average is $4.91. The last stock close price is down -29.79% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 5,718 shares of the stock were exchanged, up from an average trading volume of 5,666
In a report released on Monday September 26, 2016 Rodman & Renshaw raised the target price of Aytu BioScience (OTCMKTS:AYTU) to $9.00 indicating a possible upside of 1.61%.
See Chart Below
Aytu BioScience has a with a one year low of $3.01 and a one year high of $54.00 AYTU’s total market value is presently $0.
More About Aytu BioScience (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.